Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 2Congenital Abnormalities 2Small Cell Lung Carcinoma 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1

Interventions

Cytarabine 20Etoposide 8Mitoxantrone 7Idarubicin 5Filgrastim 5tipifarnib 4fludarabine phosphate 4Cyclophosphamide 4Topotecan 3Sorafenib 3Clofarabine 3Bortezomib 3tanespimycin 2alvocidib 2Imatinib Mesylate 2Daunorubicin 2Cord Blood Stem Cell Transplantation 2Carboplatin 2Busulfan 2Azacitidine 2Arsenic Trioxide 2Antilymphocyte Serum 2veliparib 1trebananib 1sargramostim 1romidepsin 1quizartinib 1perifosine 1octadecyl-(N,N-dimethylpiperidino-4-yl)-phosphate 1ispinesib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, Erythroblastic, Acute × Podophyllotoxin × Clear all
NCT01127009 2015-08-13

Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia

Case Comprehensive Cancer Center

Phase 1 Completed
3 enrolled
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡